Nasdaq
$0.0470▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.5MShares out 30.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 9.1Pre-market26.09.01 20:018-KKey event#●●●#●●●#●●●
BioXcel Therapeutics, Inc.Bullish
BioXcel Therapeutics has received a delisting determination from Nasdaq following its Chapter 11 bankruptcy filing, with trading of its common stock to be suspended on September 8, 2026. To secure operating capital, the company has entered into a DIP credit agreement for up to $77.25 million with affiliates of Oaktree Capital Management and the Qatar Investment Authority.…more
$0.0470+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.28Pre-market26.08.28 19:008-KKey event
BioXcel Therapeutics, Inc.
BioXcel Therapeutics filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware on August 27, 2026. The company has entered into an asset purchase agreement with Teva as a 'stalking horse' bidder for $57.5 million in cash plus the assumption of liabilities, subject to a competitive auction process.…more
$0.0470+0.00%vs prev closeView filingShare - 8.25Pre-market26.08.25 20:158-KKey event
BioXcel Therapeutics, Inc.
On August 24, 2026, BioXcel Therapeutics entered into the Fourteenth Amendment to its Credit Agreement, securing an additional $1.25 million in loans. While the minimum cash liquidity covenant was reduced from $3 million to $250,000, the company is now required to enter into definitive agreements for loan repayment or alternative capital solutions by August 31, 2026.…more
$0.0470+0.00%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.28Pre-market26.08.28 19:04#●●●#●●●
BioXcel Therapeutics Enters Asset Sale Agreement with Teva Pharmaceuticals…more
BioXcel Therapeutics has announced an agreement to sell substantially all of its assets to Teva Pharmaceuticals. This transaction marks a significant shift in the company's business operations and future direction.…more
$0.0470+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.28Pre-market26.08.28 19:00
●●●●●●●● ●●●●● ●●●●●●
BioXcel Therapeutics has initiated Chapter 11 bankruptcy proceedings to facilitate the sale of substantially all its assets. Teva Pharmaceuticals will serve as the stalking horse bidder, while the company has secured DIP financing to maintain operations during the process.…more
$0.0470+0.00%vs prev close - 8.28Overnight26.08.28 15:59
●●●●●●●● ●●●●● ●●●●●●
BioXcel Therapeutics has filed for Chapter 11 bankruptcy protection with estimated liabilities reaching up to $500 million. The company's assets are estimated to be as low as $10 million, indicating a severe financial distress.…more
$0.0470+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report